FDA Proposes Rule To Simplify Drug Manufacturing Registration
The report said the change is intended to simplify regulatory compliance while improving oversight of pharmaceutical manufacturing.
Read the full articleYou might also wanna read
US FDA proposes new rule to simplify drug manufacturing registration
The agency said the rule would improve supply chain transparency, enhance product traceability, reduce registration costs and increase regul
FDA Moves Closer to Rule That Could Push Pharma Ads Off Radio
The regulatory threat to one of radio's most profitable verticals is now a formal entry on the federal rulemaking calendar. Classifying the
Streamlined and Sponsor-Friendly: What China’s Amended Drug Regulations Mean for Pharma Companies
On January 27, 2026, China’s State Council published the amended Implementing Regulations of the Drug Administration Law, which will take ef
FDA Moves to Speed Biosimilar Development, Lower Prescription Drug Costs
The FDA has unveiled draft guidance to accelerate biosimilar approvals, reduce testing costs, and expand access to affordable biologic alter
China Finalizes Regulations for Pharmaceutical Sales Representatives
China’s 2026 Management Measures for Medical Representatives significantly expand pharmaceutical compliance obligations by imposing stricter
FDA Issues Draft Guidance on Responding to Form 483 Observations
In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483
Comments
Sign in to join the conversation.
No comments yet. Be the first.